To Evaluate the Bioavailability of a Tablet of AZD1656

A Randomized, Open, Single-Dose, Single-Centre, Cross-over, Phase I Study in Type 1 Diabetes Mellitus Patients to Estimate the Extent and Rate of Absorption of AZD1656 After Administration of a Tablet Formulation in the Fasting State and Just Before Food in Comparison With an Oral Suspension of AZD1

To evaluate the bioavailability of a tablet of AZD1656.

Inclusion Criteria:

• Male or female, type I diabetes patients, female with non child-bearing potential.
• Treated with insulin for more than 3 years. Well controlled HbA1c.
• Have a body mass index (BMI) ≥19 and ≤35

Exclusion Criteria:

• Clinically significant illness except type I diabetes, or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
• Daily use of nicotine containing substances.